AcquisitionOther
SUPERNUS PHARMACEUTICALS, INC. acquired Adamas Pharmaceuticals, Inc
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
SUPERNUS PHARMACEUTICALS, INC. -> Adamas Pharmaceuticals, Inc · $0.50,
"In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale · Strengthens Parkinson's disease portfolio with GOCOVRI® (a
Open source record (SEC) ↗